Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday. The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science...